Oligometastatic Prostate Cancer
13
8
8
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 13 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (13)
Prostate Radiotherapy and Metastasis-Directed Therapy in Synchronous Oligometastatic Prostate Cancer
5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)
Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer
Comprehensive Versus Primary Tumor Radiotherapy in Oligometastatic Prostate Cancer
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer
Maximal Tumor Eradication for Oligometastatic Prostate Cancer
The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer
Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)
Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO)
Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis
Radiotherapy for Oligometastatic Prostate Cancer
Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer